Terveystalo OyjTTALO
TTALO logo
Fair Value
€9.2
Share price24 Jun
€7.5917.5% undervalued intrinsic discount
Loading
1Y-35.13%
7D-0.52%

Earnings Will Grow Faster In 2025 With Improved Margin Outlook

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
03 Aug 25
Updated
24 Jun 26
Views
56
Not Invested

Last Update 24 Jun 26

Fair value Decreased 7.54%

TTALO: Lower Profitability Outlook Will Still Support Long-Term Upside Potential

Analysts have trimmed their price target for Terveystalo Oyj from €9.95 to €9.20, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E that collectively point to a lower fair value estimate.

What's in the News

  • Terveystalo Oyj has scheduled a Special and Extraordinary Shareholders Meeting for Jun 30, 2026, at 14:30 FLE Standard Time (source: Key Developments).
  • The company issued earnings guidance for the first half of 2026, stating that profitability in this period is expected to be below that in the first half of 2025 (source: Key Developments).
  • Both the upcoming shareholders meeting and the updated earnings guidance provide fresh context for assessing Terveystalo Oyj alongside the revised price target and valuation assumptions.

Valuation Changes

  • Fair Value: Revised lower from €9.95 to €9.20, indicating a modest reduction in the estimated equity value for Terveystalo Oyj.
  • Discount Rate: Adjusted slightly higher from 6.39% to 6.51%, reflecting a marginally higher required rate of return in the updated model.
  • Revenue Growth: Assumed long term revenue growth has been raised from 2.17% to 4.00%, using euro-based projections for the company’s top line.
  • Net Profit Margin: Margin assumption has eased from 8.40% to 8.29%, pointing to a slightly lower share of euro revenue expected to convert into profit.
  • Future P/E: Target future P/E multiple has been reduced from 13.69x to 12.20x, implying a more conservative earnings valuation for Terveystalo Oyj.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion into new public and private healthcare initiatives, as well as high-demand segments, positions the company for sustainable revenue growth and margin enhancement.
  • Accelerated digital transformation and operational efficiencies, alongside strategic M&A, support improved cost structure and increased share of higher-margin services.
  • Heavy reliance on the Finnish market, softening occupational health demand, digital execution risks, and rising labor costs threaten long-term revenue growth, margins, and market share stability.

Catalysts

About Terveystalo Oyj
    Provides occupational healthcare services in Finland, Sweden, and Estonia.
What are the underlying business or industry changes driving this perspective?
  • The introduction of the Kela 65 scheme, which allows Finnish citizens over 65 to access private healthcare at public prices, is expected to materially increase patient volumes for Terveystalo, leveraging demographic shifts and supporting sustainable revenue growth and a positive margin impact due to healthy appointment pricing.
  • Ongoing investments in digital health technology-including enhancements to service delivery, customer steering, automation, and AI within core systems-are set to improve operational efficiency and cost structure, which should drive higher net margins as digital channels gain share over brick-and-mortar and as digital transformation accelerates.
  • The increasing demand for chronic disease management and recurring care, fueled by aging and modern lifestyle factors, is likely to underpin steady long-term outpatient and diagnostic revenue streams, offering revenue stability and opportunities for higher-margin service mix optimization.
  • The revival of public sector outsourcing opportunities and increased activity in tendering for healthcare services present avenues for Terveystalo to win new contracts, supporting top-line growth and potential earnings expansion via improved capacity utilization and operational leverage.
  • Sustained focus on M&A within Finland's fragmented private healthcare market, coupled with targeted expansion in high-growth segments like dental, mental health, and occupational health, increases addressable markets and provides catalysts for revenue growth and margin improvement through synergies and operational scale.
Terveystalo Oyj Earnings and Revenue Growth

Terveystalo Oyj Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Terveystalo Oyj's revenue will grow by 4.0% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 6.2% today to 8.3% in 3 years time.
  • Analysts expect earnings to reach €115.7 million (and earnings per share of €0.85) by about June 2029, up from €76.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €146.2 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 12.2x on those 2029 earnings, down from 12.5x today. This future PE is greater than the current PE for the FI Healthcare industry at 9.8x.
  • Analysts expect the number of shares outstanding to grow by 0.13% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 6.51%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Terveystalo's core Finnish market focus increases vulnerability to local regulatory changes, economic downturns, and evolving public sector competition, as evidenced by shrinking occupational health contracts and changing customer buying behavior, which could increase revenue volatility and limit top-line growth.
  • Persistent softness in occupational health demand (a key recurring revenue stream) and declining contracted employee numbers signal structural pressure-particularly as corporate clients become more cost sensitive-potentially reducing long-term revenue growth and net margins.
  • The company's emphasis on ongoing digital transformation carries execution risk; slower-than-anticipated scale-up or failure to keep pace with digital-native competitors could erode patient volumes, lower market share, and compress future revenues and earnings.
  • Loss and termination of some outsourcing and corporate contracts, along with greater volatility and reduced public sector outsourcing volumes due to well-being counties ramping up in-house operations, suggest that revenue from portfolio businesses is at risk and net margin improvements may not be sustainable if volume weakness persists.
  • Labor cost inflation and workforce shortages-evident in the need for efficiency improvements and technology investment-could drive up the fixed cost base, compress operating margins, especially if demand remains subdued or shifts more rapidly to lower-margin telehealth services than the company can offset with efficiency gains.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of €9.2 for Terveystalo Oyj based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €10.5, and the most bearish reporting a price target of just €7.9.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €1.4 billion, earnings will come to €115.7 million, and it would be trading on a PE ratio of 12.2x, assuming you use a discount rate of 6.5%.
  • Given the current share price of €7.55, the analyst price target of €9.2 is 17.9% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Terveystalo Oyj?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

€9.2
vs €7.5917.5% undervalued intrinsic discount
PastFuture-23m1b2015201820212024202620272029Revenue €1.4bEarnings €115.7m
4%
Revenue growth
8.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Terveystalo Oyj

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued second-rate dividend payer.

Market cap€962.5m
PB1.9x
Estimated Growth4.0%
Dividend Yield8.4%
Full analysis

CEO & management

Ville Iho
CEO
3.5yrs
CEO Tenure

Provides occupational healthcare services in Finland, Sweden, and Estonia.